IriSys, a San Diego-based contract development and manufacturing organization, has been awarded a new “CRO Support for Drug Product Development, Manufacture, and Stability Studies” contract by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). The contract ordering period runs from August 1, 2017 through July 31, 2022. The reimbursement to IriSys will be up to $14.4 million.

NCATS studies and supports translational science as a scientific and operational problem, developing and supporting collaborations across traditionally separate scientific disciplines and organizations. Contracted organizations provide manufacturing, pharmacology, toxicology, regulatory, and clinical operations services to NCATS to assist with probe and assay development, lead selection and optimization, and investigational new drug applications or new drug application/biologic license application-directed studies.

This project has been funded in whole or in part with Federal funds from the NCATS, NIH, and the US Department of Health and Human Services.

Source: IriSys